Novartis has rolled forward its mid-term outlook, guiding to a 5–6% constant-currency sales CAGR for 2025–2030 and lifting peak sales expectations for two key growth drivers: Kisqali to more than $10 billion and Scemblix to more than $4 billion. The company now counts eight de-risked, in-market assets with $3–10 billion peak sales potential, expects more than 15 potentially submission-enabling readouts over the next two years, and reports a 41.2% core operating margin in the first nine months of 2025—well ahead of schedule—while signaling a return to 40%+ by 2029 after 1–2 percentage points of dilution from the planned Avidity Biosciences acquisition, anticipated to close in the first half of 2026. The guidance is underpinned by a pipeline of more than 30 potential high-value medicines, including over 10 licensed or acquired in the last two years, with most anchor assets protected by issued US patents into the 2030s.
The strategic message is clear: scale growth built on patent durability and a diversified, in-market base designed to reduce volatility. The open question is whether Novartis can convert this portfolio power into real-world access and operational throughput in an era of pricing pressure, evolving US policy, and capacity constraints in complex modalities like radioligand therapy. Raising the ceiling for Kisqali presumes continued momentum in early breast cancer, where adoption hinges on measurable, practice-changing risk reduction weighed against cost, duration, and toxicity management. Elevating Scemblix requires deeper conversion in chronic myeloid leukemia, where molecular monitoring, adherence, and long-term tolerability drive persistence and payer value narratives.
For patients, the promise is earlier intervention and broader modality choice: adjuvant CDK4/6 inhibition in breast cancer, an oral STAMP inhibitor in CML, self-administered anti-CD20 therapy in multiple sclerosis, and an oral complement inhibitor in PNH. For payers, the implication is budget stress from multiple multi-billion-dollar franchises maturing in parallel, just as GLP-1s and cardiometabolic therapies reset macro spending. Expect tighter indication management, outcomes-linked contracts, and heightened scrutiny of line-of-therapy expansions. For HCPs and systems, practical barriers loom large: radioligand therapy requires facility readiness, isotope supply reliability, and workflow redesign; Leqvio’s buy-and-bill dynamics and outcomes positioning need coordination across cardiology and primary care; hematology and oncology practices must scale diagnostics and real-world data capture to sustain value claims.
Competitors will read this as a marker. In HR+ breast cancer, the bar for differentiation against the CDK4/6 class tightens around adjuvant efficacy and tolerability in broad populations. In neurology, the shift to subcutaneous anti-CD20 regimens pressures infusion-based incumbents to respond on convenience and total cost. In cardiometabolic and rare hematology, the contest pivots to delivery models and longitudinal evidence that tie adherence to hard outcomes. Meanwhile, the planned Avidity deal signals a continued pivot toward modular, externalized innovation platforms—part of an industry-wide move from megamergers to serial bolt-ons that refresh pipelines without overwhelming integration risk.
The next two years, with more than 15 potential submission-enabling readouts, will test whether pipeline density translates to filing velocity and launch quality. Success will depend less on headline efficacy and more on access strategy, evidence operations, and modality-specific scaling. The forward test for Novartis and its peers is whether they can sustain 40%+ margins while expanding capacity-heavy platforms like radioligand therapy, integrating RNA-conjugate technologies, and defending premium pricing under intensifying policy and payer scrutiny—can a multi-blockbuster strategy remain margin-accretive when real-world performance becomes the dominant currency of value?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
